<DOC>
	<DOCNO>NCT01535638</DOCNO>
	<brief_summary>The primary objective current study investigate relative bioavailability three trial formulation BI 207127 , trial formulation 2 ( TFII ) , final formulation ( FF ) , FF modify formulation . All formulation supply film-coated Tablets administer single dose treatment BI 207127 ( 3 film-coated Tablets ) healthy volunteer , aim compare bioavailability three formulation . All treatment apply fed , 30 minute start intake standard normal breakfast .</brief_summary>
	<brief_title>Bioavailability 3 Different Formulations BI 207127 Healthy Male Volunteers</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : 1 . Healthy male accord complete medical history , include physical examination , vital sign ( blood pressure ( BP ) , pulse rate ( PR ) ) , 12lead electrocardiogram ( ECG ) , clinical laboratory test 2 . Age =21and Age =50 year 3 . Body mass index =18.5 BMI = 29.9 kg/m2 4 . Signed date write informed consent prior admission study accordance Good Clinical Practice ( GCP ) local legislation . Exclusion criterion : 1 . Any finding medical examination ( include BP , PR ECG ) deviate normal clinical relevance 2 . Any evidence clinically relevant concomitant disease 3 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 4 . Surgery gastrointestinal tract ( except appendectomy ) 5 . Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder 6 . History relevant orthostatic hypotension , faint spell blackouts 7 . Chronic relevant acute infection 8 . History relevant allergy/hypersensitivity ( include allergy drug excipients ) 9 . Intake drug long halflife ( &gt; 24 hour ) within least 10 halflifes prior administration trial drug trial 10 . Use drug might reasonably influence result trial within 10 day prior administration trial 11 . Participation another trial investigational drug within two month prior administration trial drug trial 12 . Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) 13 . Alcohol abuse ( 40 g/day ) 14 . Drug abuse 15 . Blood donation ( 100 mL within four week prior first administration trial drug trial ) 16 . Excessive physical activity ( within one week prior first administration trial drug trial ) 17 . Any laboratory value outside reference range clinical relevance 18 . Inability comply dietary regimen trial site 19 . A marked baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc interval &gt; 450 m ) 20 . A history additional risk factor Torsades de point ( TdP ) ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) 21 . History photosensitivity recurrent rash 22 . Subject willing avoid sun exposure first administration trial drug end study .</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>